Blenrep (belantamab mafodotin-blmf)
New biologic
- Region
- 🇺🇸 US
- Active substance
- belantamab mafodotin-blmf
- Company
- Glaxosmithkline Llc
- Status
- Approved
- FDA approval
- Thu 23 Oct 2025
- Designations
- New biologic
- Application
- BLA761440
- Official record
- www.accessdata.fda.gov
Regulatory milestones
Thu 23 Oct 2025🇺🇸 FDA approval
FDA approves Blenrep (belantamab mafodotin-blmf), a new medicine
Glaxosmithkline Llc; BLA761440; New biologic; injectable · source
Follow Blenrep
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.